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Background: Overall survival of HER2 positive metastatic breast cancer patients has been significantly improved
with inclusion of trastuzumab to chemotherapy. Several studies have demonstrated discordant HER2 status in the
primary and metastatic tumour. However, rates of discordance vary considerably in published reports.
Methods: Information collected prospectively was analysed for all patients seen from 1999 to 2009 with primary
breast cancer and who had biopsy of a local or distant recurrence. Patients were included if adequate tissue was
available from both paired samples. Recurrent samples included fine needle aspirations, core and excisional
biopsies. HER2 status in all paired samples was assessed by in-situ hybridisation by a single pathologist in a national
reference laboratory. This was compared with HER2 immunohistochemistry results provided in the course of routine
diagnosis at regional laboratories.
Results: In total, 157 patients with recurrent (n = 137; 87.3%) or synchronous primary and metastatic (n = 20;
12.7%) breast cancer had biopsy of the metastatic site. The study population comprised of 116 patients with
adequate tissue in both primary and metastasis. The concordance between HER2 status of the paired samples by
local immunohistochemistry testing and central in-situ hybridization were 78% and 99%, respectively. Only one
patient demonstrated HER2 discordance – primary lesion was positive whilst a metastatic site was negative.
Conclusions: This single institution study demonstrated a low rate of HER2 discordance between primary and
recurrent breast cancer as assessed by in-situ hybridisation. This contrasts to results reported by others, which may
be explained by differences in study methodology, definition of recurrent disease samples and generally small
numbers of patients assessed. Despite the current findings, the decision to obtain metastatic tissue for evaluation is
influenced by other factors. These include disease-free interval, which may raise the possibility of a new malignancy
and the accuracy of initial HER2 assessment of the primary tumour.
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Optimal management of metastatic breast cancer
requires accurate identification of the biological charac-
teristics of the recurrent disease. In human epidermal
growth factor receptor 2 (HER2) positive metastatic
breast cancer, the clinical benefit of trastuzumab-based
therapy is well established when compared with chemo-
therapy alone [1,2].* Correspondence: arlenechan@me.com
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reproduction in any medium, provided the orFurther, it is established that the benefit of anti-HER2
therapy is largely achieved in those patients whose
tumours are confirmed as being positive, either by 3+
HER2 protein expression on immunohistochemistry
(IHC) or gene amplification by in-situ hybridization
(ISH).
Retrospective studies have suggested that there may be
clinically significant discordance between HER2 receptor
status when comparing primary with recurrent/metastatic
breast cancer of up to 42% [3-5]. Studies employing IHC
have generally found higher discordance rates than those
employing in situ hybridization, suggesting methodologicaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tors, which may influence the rates of discordance between
paired samples, include whether the same method of
HER2 assessment is used for the primary and recurrent
specimens [6,7].
To enable optimal management of this patient group,
it is important to understand if the reported incidence of
change in HER2 status of primary and metastatic breast
cancer is real or an artefact of testing methodology. In
the absence of definitive studies which use uniform
methodology in the assessment of discordance between
primary and recurrent breast cancer, retrospective single
institution reports may provide some understanding of
the significance of this occurrence.
The current study was undertaken to assess for the in-
cidence of HER2 status of both primary and metastatic
recurrence in patients from a single institution assessed
in a high volume reference laboratory using uniform
methodology, namely in-situ hybridization.Methods
Study design
This is a retrospective, single center study, aimed to in-
vestigate the rate of HER2 neu discordance between pri-
mary breast carcinoma and locoregional or metastatic
disease in patients seen by a single clinician at the
Mount Hospital between 1999 and 2009.
Patient personal details were non-identifiable and all
patients had provided written consent to their medical
information being used for research purposes. The study
was approved by the Mount Hospital Ethics and Re-
search Committee and conducted in accordance with
the Helsinki declaration.Study population
The study population comprised those patients who had
adequate tissue available from paired primary and recur-
rent tumour samples for assessment of HER2 amplifica-
tion. Patients who presented with primary breast cancer
and synchronous metastatic disease who underwent bi-
opsy of the metastatic lesion were also included. Patient
demography, local laboratory determination of breast
cancer pathological characteristics, management of pri-
mary and recurrent disease and follow-up information
had been recorded prospectively over time in a secure
database. Although the analysis was conducted retro-
spectively, source verification of entered data was pos-
sible given the nature of data collection. Primary breast
cancer tissue sections were obtained from formalin-fixed
paraffin embedded blocks and recurrent tumour samples
were collected mainly as core biopsies or cell blocks pre-
pared from centrifuged fine needle aspirations.HER2 assessment
HER2 status was assessed on paraffin sections by either
single probe silver in situ hybridization (SISH: Ventana
Inform HER2 assay) on Ventana XT automated stainer,
or fluorescence in situ hybridization (FISH: Vysis/Abbott
PathVysion HER2/cep17 dual colour assay). Overnight
hybridization was employed in both assays. FISH was
employed as either the primary assay in cases received
for testing prior to 2006, or as a confirmatory assay in
cases received after 2006 with non-diagnostic or equivo-
cal SISH results. A positive FISH result was classified as
a HER2/cep17 ratio >2.2 (high level amplified = ratio
>4), and a positive single probe SISH result was classi-
fied as HER2 copy number >6 (6–10 low level amplified;
>10 high level amplified). A negative polysomic result
was defined as having mean HER2 copies >2.5 but < 4
(diploid <2.5). Cases with 4–6 mean copies on single
probe SISH were regarded as equivocal and re-assessed
by FISH. All cases were scored by a single pathologist
(AM), blinded as to the status of the paired sample.
Statistical consideration
The agreement between the HER2 gene amplification
status of the primary and recurrent lesion was assessed
using a kappa test. All other variables are reported as a
proportion of the eligible population where HER2 ampli-
fication status was possible on paired tumour samples.
Results
Patient characteristics
Over the 10 years study period, 157 women with recur-
rent (n = 137; 87.3%) or synchronous primary and de
novo metastatic (n = 20; 12.7%) breast cancer underwent
biopsy of the recurrence or metastatic site, respectively.
Forty-one patients were excluded from this study due to
insufficient tissue being available for central analysis;
thus 116 patients constitute the study population.
Thirty-six of the study patients (31%) were HER2 posi-
tive (3+) by local IHC testing of the primary tumour. Pa-
tient and tumour characteristics of the study population
and those who had a recurrence biopsy but were ineli-
gible are shown in Table 1. Patients in the study group
were more likely to have had a recent breast cancer
diagnosis with less than a 2-year interval between the
paired biopsies. Of the 102 patients in the study popula-
tion who presented with early breast cancer, the majority
of tumours were invasive ductal (84.6%), grade 2 or 3
(93.1%) or associated with positive lymph nodes (80.2%)
(Table 2). Eighty percent of patients received adjuvant
chemotherapy with 10 patients receiving adjuvant trastu-
zumab in the context of a clinical trial.
At the time of disease recurrence, 29 patients received
HER2 targeted treatment in the first-line metastatic set-
ting. Median duration of HER2 targeted treatment in
Table 1 Patient and breast cancer characteristics
Study population Ineligible population p
valuen=116 n=41
Number (%) Number (%)
Age at diagnosis
Median (yrs) 50 50
Range (31–85) (34–73)
Year breast cancer diagnosis
Pre - 2000 26 (22) 20 (49)
2000–2001 19 (16) 6 (15) 0.01
2002–2003 29 (25) 3 (8)
2004–2005 21 (18) 9 (23)
2006–2007 16 (14) 2 (5)
2008-2009 5 (4) 1 (3)
Disease interval to biopsy (yrs)
0 (metastatic at diagnosis) 9 (8) 5 (12)
0.5 – 2y 29 (25) 2 (5) 0.02
2.1 – 5 44 (38) 14 (34)
>5y 34 (29) 20 (49)
Type of biopsy
Local recurrence site 40 (34) 7 (17) 0.05
Distant recurrence site 76 (66) 34 (83)
Site of recurrent or metastatic biopsy
Breast 24 (20) 3 (7)
Lymph nodes 20 (17) 10 (24)
Chest wall / Skin 18 (16) 4 (10) 0.13
Bone 14 (12) 9 (22)
Liver 9 (8) 5 (12)
Brain 9 (8) 2 (5)
Lung 7 (6) 0
Others 15 (13) 8 (20)
Type of tissue biopsy
Fine needle aspiration 34 (29) 13 (32) 0.84
Core / Excisional biopsy 82 (71) 28 (68)
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slightly shorter duration of treatment exposure in those
patients who had received adjuvant trastuzumab com-
pared to those who had not (median 8.3 months vs 9.4
months, respectively).
HER2 Concordance rates
Local evaluation of the primary and recurrent lesion by
IHC is shown in Table 3, with 78% concordance between
the paired samples when categorising as negative (0 or 1+),
inconclusive (2+) or positive (3+). In contrast, central
analysis of paired samples demonstrated 99% concor-
dance between the primary and paired recurrence biop-
sy with respect to HER2 amplification status as assessed
by ISH, when status was classified as either positive ornegative (Table 4). The kappa score for paired samples
as assessed by immunohistochemistry was 0.616, which
demonstrates good agreement. For in situ hybridisation,
the kappa score of 0.979 (95% CI 0.939 – 1.02) indicates
very good agreement.
The only patient to demonstrate apparent genuine
change in status was a 78 yr old woman who was diag-
nosed with HER2 amplified left breast cancer (HER2/
cep17 FISH ratio = 4.1) and subsequently developed
metastatic recurrence in the bones, 34 months later.
Biopsy of the sacrum demonstrated metastatic breast
cancer and the patient was commenced on trastuzumab-
based treatment, in a clinical trial setting. Following 28
months of objective disease control, she developed pro-
gressive bone disease and locoregional recurrence in the
Table 2 Characteristics of breast primary in study
population














ER and/or PR positive 74 (63.8)




Neoadjuvant or Adjuvant treatment
Nil or non-compliant 14 (13.7)
Endocrine only 6 (5.9)
Non-anthracycline chemotherapy 11 (10.8)
Anthracycline-base chemotherapy 38 (37.3)
Anthracycline and taxane 29 (28.4)
Taxane only 4 (3.9)
Adjuvant trastuzumab 10 (8.6)
Disease-free interval, median (range) 36.3 (26.2 – 135)
Table 4 HER2 status of primary and matched recurrent








Negative 53 11 0 0
Negative
Polysomic
9 6 0 0
Low
Amplified
0 0 (2*) 2 5
High
Amplified
1 0 1 26
The 2* cases which did not contain breast malignancy upon central review
were excluded.
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mean HER2 gene copy number of 2.97 consistent with
polysomy. She continued treatment with trastuzumab-
based therapy with the addition of endocrine treatment
and continues to have responsive disease to the present
time (64 months). Nine patients who had received adju-













HER2 positive 2 3 22
Total 56 16 26
*Eighteen patients, where immunohistochemistry was not performed by the
local laboratory on primary or recurrence, were excluded.disease; in all cases, the metastatic lesion remained con-
cordant for HER2 positivity by in situ hybridisation.
Two patients with HER2 amplified primary breast can-
cers had apparent negative HER2 ISH status in metastatic
deposits (brain and pleural fluid respectively) at initial
blinded assessment. Subsequent histological examination
and IHC on the brain lesion confirmed it was an unrelated
primitive ectodermal primary brain tumour. Additional
IHC on the pleural fluid cell block confirmed the presence
of reactive mesothelial cells only. These cases were thus
retrospectively classified as “ineligible” due to the absence
of assessable metastatic breast cancer, but have been
included in Table 3 for completeness.
Discussion
Several publications have reported discordance in the
HER2 status between primary breast cancer and meta-
static disease. The alteration in the HER2 status from
positive to negative has ranged from 2% to 42%. Changes
in the HER2 status in the opposite direction has also
been reported, with some authors reporting rates of up
to 37%. The variation in reported results may relate to
several factors. These include the method used to eva-
luate HER2 status in the paired specimens, the definition
of “metastatic” tissue to which the primary HER2 status
is compared, whether HER2 status is evaluated through
the detection of gene amplification in tissue sections or
as circulating HER2 protein levels, and whether anti-
HER2 treatment is administered to patients prior to
obtaining the second specimen.
Our study underscores the difficulties in assessing
paired primary and recurrent tumour specimens when
analysis is performed in a retrospective fashion with 26%
of specimens having insufficient material available for in
situ hybridisation. Although the majority of patients had
core or excisional biopsies of the recurrent lesion, there
was still inadequate tissue available for central assess-
ment in a significant proportion of patients. Giotta et al.
demonstrated in a small study of 20 patients that it was
feasible to perform in situ hybridisation on cytological
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[8]. They reported a HER2 discordance rate of 10% with
one negative primary lesion becoming amplified in a
subsequent lung metastasis; and one HER2 amplified
primary lesion being associated with loss of amplification
in a liver metastasis.
There have been conflicting results in studies that have
assessed HER2 status with a combination of immunohis-
tochemistry and in situ hybridisation of the primary and
metastatic lesion (Table 5). The HercepTestTM (Dako,
Glostrup, Denmark) or FISH were used in a study of
100 paired primary and metastatic samples, where a
discordance rate of 6% was found, with all 6 cases
showing HER2 overexpression in the metastatic lesion
compared to the HER2-negative primary tumour [9].
Metastatic samples included biopsies from bone, soft
tissue and viscera. Fluorescent in situ hybridisation was
only possible in 68 paired samples and there were 5 dis-
cordant cases (7%); 3 metastases gaining amplification
vs a non-amplified primary, and 2 metastases becoming
non-amplified. The study identified 11% of cases
which were negative on immunohistochemistry but
confirmed as positive on in situ hybridisation [9].
Thus, the authors concluded that re-biopsy of a metas-
tasis for the purpose of confirming HER2 status of the
recurrence was not supported with the exception of pri-
mary tumours assessed as HER2 negative on immuno-
histochemistry alone, where biopsy of a recurrence for
analysis by in situ hybridisation was indicated. Recently,
Niikura et al. identified forty-three (24%) of the 182
patients with HER2 positive primary tumors as having
metastatic tumors which were HER2 negative [10].
However the authors accepted both IHC3+ and ISH+
results as indicators of positive primary status without
central review of these specimens for the purposes of
their study [10]. The majority of the patients had beenTable 5 Summary of studies reporting HER2 status in







Giotta [8] 20 5% 5%
Gancberg [9]:
Immunohistochemistry 100 6% -
In situ hybridisation 68 4% 3%
Nikura [10] 182 - 24%
Amir [11] 83 8% (6/73) 20% (2/10)
Gong [12] 60 1.6% 1.6%
Tapia [13] 105 1.9% 0.9%
Fabi [14] 137 8.7% 1.5%
Simon [15] 122 2.2% 6.5%
Lindstrom [16] 76 6.5% 10.5%treated with adjuvant chemotherapy and trastuzumab.
They reported significantly higher rates of HER2 dis-
cordance in those patients who had received adjuvant
chemotherapy compared to those who had not. These
authors argued strongly for re-biopsy of metastatic
lesions to accurately plan management [10]. In the same
issue of the journal, Amir et al. reported their prospect-
ive study of patients presenting with imaging suggestive
of metastatic disease or who were experiencing progres-
sion while receiving palliative systemic treatment [11].
The authors demonstrated discordance in HER2 status
(as assessed by FISH) in 9.6% of 83 assessable patients
(gain in 6/73, loss in 2/10); and concluded that biopsy of
metastases was feasible and led to change in systemic
therapy in 14% of patients [11].
Gong et al. compared primary tumour with loco-regional
and distant recurrence in 43 and 17 patients, respectively
[12]. Thirty-two patients had received chemotherapy in the
period between the primary and recurrence biopsies. It
was possible to examine HER2 status by fluorescent in situ
hybridisation on paraffin-embedded tissue or fine needle
aspirates. All but 2 of the 60 tumours were concordant;
one case demonstrated HER2 negative primary from one
of three multifocal lesions, whilst the axillary nodal metas-
tasis was positive. The second case showed amplification in
the primary but not in the liver metastasis. Therefore
HER2 status was reliably assessed in the primary with 97%
concordance and it was considered that the HER2 status
remained stable during the metastatic process [12].
Tapia et al. reported an initial discordance rate of 7.6%
in 105 patients whose primary and metastatic lesions
had undergone HER2 evaluation by FISH on primary
histological and metastatic cytological specimens [13].
The 8 discordant cases were re-evaluated by FISH and 5
of the cases were found to be concordant. Reasons for
the discordant initial assessment included interpre-
tational error with the HER2/reference ratio being close
to 2.0 in three patients, and re-evaluation identified the
presence of scanty amplified malignant cells which had
been initially overlooked in two patients [13]. The
authors concluded that HER2 gene status remains highly
conserved between primary and metastatic disease with
a final concordance rate of 97.1% in their sample [13]. In
contrast to these studies, a recent report by Fabi et al. in
137 patients diagnosed between 1999 and 2006 demon-
strated a discordance rate of 10%, 12 primary lesions
being HER2 negative whilst the paired metastasis was
positive; and 2 patients with a change in the HER2 status
in the opposite direction [14]. The strength of this study
was uniform use of silver in situ hybridisation (SISH) for
assessment of the paired samples. A further finding in
this group was the significant increase in gene copy
number in the metastases of tumours that were ampli-
fied in the primary lesion as defined by SISH [14].
Chan et al. BMC Cancer 2012, 12:555 Page 6 of 7
http://www.biomedcentral.com/1471-2407/12/555Simon et al. evaluated tissue microarrays of primary
tumour and lymph node positive metastases, where the
HER2 status was assessable in 125 patients. In this pa-
tient group, a discordance rate of 7.2% (9 patients) was
found overall. However, only 2 patients had nodal me-
tastases, which were uniformly discordant to the primary
tumour. The remaining patients had nodal metastases in
which some showed HER2 concordance with the pri-
mary tumour, illustrating the heterogeneity that may
exist [15]. A recent Swedish study demonstrated 14.5%
discordance between the primary and metastatic lesion;
although this frequency increased to 50% when consid-
ering those tumours, which converted to or maintained
oestrogen negativity in the metastases [16].
Several groups have assessed the impact of systemic
treatment with or without HER2 targeted therapy on
subsequent tumour HER2 status. Results on 142 HER2-
positive patients (defined as IHC 3+ or amplification on
ISH) treated with neoadjuvant anthracyclines, taxanes
and trastuzumab over the period 2004–2007 were
reported from the MD Anderson Cancer Centre. In 25
patients with sufficient residual invasive tumour, com-
parison of HER2 status by FISH was performed [17].
Eight patients (32%) had residual disease which was
HER2 negative and at median follow-up of 37 months,
this group of patients had significantly inferior relapse-
free survival compared to those patients whose residual
disease remained HER2 positive [17]. These results con-
trast with a study, which utilised immunohistochemistry
to evaluate HER2 status in residual disease in the breasts
of 15 patients receiving anthracycline-based neoadjuvant
therapy (trastuzumab was not given) and 44 patients
with metastatic disease who underwent surgical resec-
tion or biopsy of localised liver or lung metastases [18].
In both patient groups, patients who had HER2 positive
disease at baseline evaluation were found to have identi-
cal HER2 over-expression in the residual disease (11 of
13 breast specimens; and 9 of 9 metastases).
No cases of heterogeneous HER2 amplification were
detected in our study cohort, although two cases were
noted to be heterogeneous with respect to the presence of
polysomy. The incidence of heterogeneity of HER2 status
in breast cancer (as determined by ISH) is variably esti-
mated at up to 11%, and this may underlie some of the
cases of “genuine” HER2 status change, reflecting out-
growth of an undetected clone [19]. Re-assessing HER2
status in metastatic deposits of any case exhibiting hetero-
geneity in the primary tumour would appear to be
warranted.
Conclusion
In conclusion, the present study is one of the largest
studies where paired primary and recurrence tissue sam-
ples were available for centralised ISH analysis. Thelimitations of a retrospective review does not permit the
results to impact on current clinical practice, but our
study does provide further evidence confirming a very
low incidence of change in the HER2 status between pri-
mary and recurrent breast cancer when a uniform and
reliable methodology is employed. To avoid misinter-
pretation of discordance rates between paired samples
over time, our study would indicate that it is important
to use the same method of HER2 assessment on the pri-
mary and recurrence specimens. Further we have
demonstrated that in situ hybridisation is more accurate
than immunohistochemistry and less susceptible to sam-
ple processing variables.
It is not possible to fully explain the variation in
reporting of HER2 discordance rates in the literature,
but factors include small numbers (<100) of patients
evaluated, including those where the actual number of
paired samples studies were less than the entire cohort.
The use of a combination of immunohistochemistry and
in situ hybridisation or other non-standard methods of
evaluation (such as automated subcellular localization
and quantification of protein expression multiplex
ligation-dependent probe amplification) may also in-
fluence the interpretation of results.
Although the current study did not demonstrate dis-
cordance in HER2 status such that management of re-
current disease was altered, there exists the possibility
that apparent recurrent breast cancer may be a new pri-
mary malignancy and therefore factors such as long
disease-free interval, atypical radiological appearance
and clinical judgement as to the baseline breast cancer
risk and suspicion of recurrence needs to be considered.
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